Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2001, p. 1934-1936, Vol. 45, No. 6
Mycobacteriology Unit, Institute of Tropical
Medicine, Antwerp, Belgium,1 and
Institute of Medical & Veterinary Science, Adelaide,
Australia2
Received 3 November 2000/Returned for modification 18 December
2000/Accepted 16 March 2001
Two novel systems were evaluated for performing indirect kanamycin
susceptibility tests on 72 strains of Mycobacterium
tuberculosis. The microplate Alamar blue colorimetric method
(breakpoint, 2.5 µg/ml) and the Mycobacterium Growth Indicator Tube
(MGIT) system (breakpoint, 5.0 µg/ml) both produced 98.6% agreement
when compared with the conventional proportion method performed on 7H10
agar using 5.0 µg of kanamycin/ml. Both systems provided
results within an average of 1 week.
Multidrug-resistant tuberculosis
(MDRTB), defined by isolates of Mycobacterium tuberculosis
resistant to isoniazid and rifampin, is a significant public health
problem in several countries, particularly those that comprised the
former USSR (3, 6, 7, 15). Laboratories supporting
TB control programs in populations of these countries with endemic
MDRTB are increasingly required to provide rapid, reliable drug
susceptibility testing (DST) not only for the first-line drugs (i.e.,
isoniazid, rifampin, ethambutol, and streptomycin) but also for
second-line agents (e.g., kanamycin and the quinolones) (3,
14). Unfortunately, the protocols for performing second-line DST
are not standardized and the recommended critical concentrations for
the various media are often based on scattered small-scale studies
(1, 10). Collaborative efforts have already attempted to
optimize the methods for performing second-line DST on solid media and
by the radiometric BACTEC method (Becton Dickinson Diagnostic
Instrument Systems, Sparks, Md.) (18). This study
continues this process by evaluating the microplate Alamar blue (MAB)
colorimetric method (8, 16, 21) and the Mycobacterium
Growth Indicator Tube (MGIT) system (4, 17, 19) for
performing kanamycin susceptibility tests.
A panel of M. tuberculosis strains was compiled comprising
68 clinical isolates sent to the World Health Organization (WHO) Supranational Reference Laboratory in Antwerp, Belgium, from Azerbaijan (n = 42), Siberia, Russia (n = 16),
Georgia (n = 8), and Kazakhstan (n = 2) and four reference strains, ATCC 35826, ATCC 35827, ATCC 35828, and ATCC 35830 (all from American Type Culture
Collection, Manassas, Va.), with known monoresistance to cycloserine,
kanamycin, pyrazinamide, and ethionamide, respectively. The clinical
isolates had been characterized as kanamycin resistant or
susceptible by using the conventional proportion method
(5), Middlebrook 7H10 agar, and recommended
parameters (e.g., a critical proportion of 1% and a critical
concentration of 5.0 µg/ml) (11, 13, 18). The
panel was maintained on Löwenstein-Jensen medium and freshly
subcultured in 7H9-S broth (Middlebrook 7H9 supplemented with 0.1%
Casitone, 0.5% glycerol, and oleic acid, albumin, dextrose and
catalase [OADC; Becton Dickinson Microbiology Systems]) prior to evaluation. A stock solution of kanamycin (1 mg/ml) was prepared from chemically pure powder (Roche, Brussels, Belgium), filter sterilized, and kept in aliquots at For the MAB procedure, 0.1 ml of 7H9-S broth containing serial
dilutions of kanamycin (to provide final drug concentrations of 0.5 to
20 µg/ml) was dispensed into the wells of a 96-well flat-bottom
microtiter plate (Falcon; Becton Dickinson Labware, Franklin Lakes,
N.J.). Inocula were prepared from 5- to 7-day-old 7H9-S broth
cultures, the turbidity was adjusted to a 0.5 McFarland standard, and
0.1 ml of a 1:5 dilution was added to the test wells. A growth control
well containing no antibiotic and a sterile control well were also
prepared for each specimen. The plate was covered, sealed in a
polyethylene bag, and incubated at 37°C in normal atmosphere. After 6 or 7 days, 20 µl of the Alamar blue indicator (10× sterile
solution) and 20 µl of 10% Tween 20 were added separately to
all wells and the plate was reincubated overnight. Mycobacterial growth
was indicated by a blue-to-pink color change. The MIC was defined as
the lowest concentration of kanamycin that prevented a color change.
For the MGIT DST, an inoculum was prepared as described for the MAB
assay or by vortexing a 1- to 3-day-old positive MGIT tube for 10 s and pipetting 1 ml of the medium into 4 ml of sterile saline (1:5
dilution) (19). Aliquots (0.5 ml) of this inoculum were
added to two MGIT tubes that had been supplemented with 0.5 ml of OADC;
one tube also contained kanamycin at a final concentration of 5.0 µg/ml. The tubes were tightly capped and incubated in normal atmosphere at 37°C. Starting on day 3 after inoculation, the tubes were examined daily using a 365-nm UV transilluminator as previously described (4, 17, 19). An isolate was considered
susceptible if the drug-containing tube did not fluoresce within 2 days
of the drug-free tube; conversely, if the drug-containing tube
fluoresced before or within 2 days of the drug-free tube, the strain
was defined as resistant. By including a series of tubes containing dilutions of kanamycin between 1 and 20 µg/ml, the MGIT system was
also used to perform kanamycin MIC determinations in the initial stages
of the study and for specimens producing discordant results. The MIC
was defined as the lowest concentration of kanamycin that prevented the
drug-containing tube from fluorescing within 2 days of the drug-free tube.
The MAB and MGIT assays were performed in parallel, and the results
read visually by one observer (I.B.). In both assays, the tests were
compared with growth and sterile controls; only those tests with color
development or fluorescence equivalent to that of the growth control
were considered positive. For strains producing results discordant with
the proportion method, the discordant assay was repeated, as
was the proportion method test on 7H10 and 7H11 Middlebrook agar
(10, 12, 18).
Previous studies have reported that wild-type kanamycin-susceptible
M. tuberculosis strains require MICs of 3 µg/ml or less when tested on 7H11 agar or in BACTEC 7H12 broth (1,
10). The MAB method using 7H9-S broth yielded similar results
(Table 1). Thirty-six of 37 kanamycin-susceptible strains required MICs of 2.5 µg/ml or less
while all 35 kanamycin-resistant strains required MICs of 5.0 µg/ml
or greater. For these 72 M. tuberculosis strains, the
greatest concordance (98.6%) between the MAB and conventional
proportion methods was achieved when a breakpoint concentration of 2.5 µg/ml was used in the MAB assay.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.6.1934-1936.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Kanamycin Susceptibility Testing of Mycobacterium
tuberculosis Using Mycobacterium Growth Indicator Tube and a
Colorimetric Method
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
20°C until use.
TABLE 1.
Distribution of MICs of kanamycin by MAB assay for
panel of 72 M. tuberculosis strainsa
As an initial step in evaluating kanamycin DST by MGIT, this study used the MGIT system to determine the MICs for eight kanamycin-susceptible strains (five clinical isolates and three ATCC strains) and four kanamycin-resistant strains (three clinical isolates and one ATCC strain). All eight susceptible strains required MICs of 2.5 µg/ml or less, while the MICs for the four resistant strains were greater than 20 µg/ml. A critical concentration of 5 µg/ml was therefore chosen as the breakpoint for evaluating kanamycin DST by MGIT. This breakpoint was also considered justifiable because 5 µg/ml is the recommended critical concentration for kanamycin susceptibility testing in several media (e.g., BACTEC 7H12 broth) (11, 13, 18).
Using this breakpoint concentration, the initial kanamycin DST by MGIT
produced three discordant results compared with the conventional
proportion method when testing the panel of 72 M. tuberculosis isolates. One strain (98-1825) was confirmed
as "false resistant" by MGIT, requiring a MIC of
2.5 µg/ml by
MAB but a MIC of >5.0 µg/ml by MGIT on repeated occasions;
supplemental testing by the conventional proportion method on 7H10 and
7H11 agars verified that this isolate was truly kanamycin susceptible. However, two other isolates that were repeatedly "susceptible" by
MGIT were classified as "resistant" by the original proportion method tests, but supplemental investigations on 7H10 and 7H11 agars
found that these two strains were kanamycin susceptible. Sequencing of
the 16S rRNA gene supported the final classification of these two
initially discordant strains as kanamycin susceptible (data not shown),
finding no mutations commonly associated with kanamycin resistance
(i.e., at positions 1400, 1401, and 1483) (20). The
ultimate concordance of the MGIT system with the proportion method was
therefore 98.6%. The other performance characteristics of the MGIT
system were as follows: sensitivity, 100% (95% confidence interval
[CI], 90.0 to 100%); specificity, 97.3% (95% CI, 85.8 to 99.9%);
predictive value for resistance, 97.2% (95% CI, 85.5 to 99.9%);
predictive value for susceptibility, 100% (95% CI, 90.3 to 100%).
The mean turnaround time for these indirect kanamycin DSTs by MGIT was
5.1 days (range, 3 to 14).
MDRTB strains often demonstrate resistance to other first-line drugs and occasionally to second-line agents, such as kanamycin. For example, studies of MDRTB strains from two prisons in areas of the former USSR have reported that 97.1% are streptomycin resistant (6) and 15.5% are kanamycin resistant (3). Considering the widespread and uncontrolled use of kanamycin in areas of the former USSR (7), this high rate of resistance is not surprising but is alarming. A quinolone and a cheap injectable agent, such as kanamycin, form the basis of effective treatment regimens for MDRTB (2, 12), but kanamycin resistance produces cross-resistance with amikacin (1), leaving the expensive polypeptide capreomycin as the only effective injectable agent (2, 3, 12).
Laboratories supporting TB services in areas of the former USSR and other areas where MDRTB is endemic must therefore be able to provide prompt, reliable DSTs for kanamycin. Protocols have been described for performing kanamycin DST by the conventional proportion method on solid media and by BACTEC (1, 11, 13, 18). However, the conventional method requires 3 to 6 weeks for completion while BACTEC, which involves the use of radioisotopes and machinery, is a rapid but inappropriate technology for low-resource countries. In contrast, the manual MGIT system uses a fluorescence quenching-based oxygen sensor and can be read visually with a simple Wood's lamp. Previous studies from high-income countries have validated the system for first-line DST (4, 17, 19). The system is robust, safe, and simple and has been easily implemented in a TB laboratory in a Siberian prison hospital (9). This study has now demonstrated that the MGIT system can provide accurate indirect kanamycin susceptibility results within an average of 5.1 days. In fact, cost is the only factor prohibiting widespread application of the MGIT system.
The MAB method is a cheaper alternative that can also provide indirect DST results within 1 week without the need for expensive machinery. Studies in high- and low-income countries have validated the MAB method for first-line DST (8, 16, 21). Using the microplate format and selected critical concentrations, the reagent costs for performing susceptibility testing for first-line drugs and kanamycin could be less than $1 per isolate. However, the MAB method requires a greater level of technical expertise to provide reliable results. Furthermore, the microplates do not have a tight seal and may represent a biohazard unless handled carefully in the laboratory.
In summary, this study has demonstrated that the MGIT and MAB systems can provide indirect kanamycin DST results within an average of 1 week and with 98.6% agreement with the conventional proportion method. While further studies with larger isolate collections are required to confirm the optimal breakpoint concentrations, these two systems appear to be appropriate techniques for performing rapid indirect kanamycin susceptibility tests in low-resource settings where MDRTB is endemic, where such tests are increasingly required.
| |
ACKNOWLEDGMENTS |
|---|
These studies were funded by the Damien Foundation Belgium and the "Belgische Bond Tegen de Tuberculose." BD Biosciences-Europe provided the MGIT media. I.B. was supported by a Neil Hamilton Fairley Fellowship (987069) from Australia's National Health and Medical Research Council.
We thank our colleagues in the International Committee of the Red Cross, Médecins sans Frontières, and the Ministry of Justice in Siberia for their cooperation.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institute of Medical & Veterinary Science, P.O. Box 14, Rundle Mall, SA 5000, Australia. Phone: 61 8 8222-3000. Fax: 61 8 8222-3543. E-mail: ivan.bastian{at}imvs.sa.gov.au.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Allen, B. W., D. A. Mitchison, Y. C. Chan, W. W. Yew, and W. G. L. Allan. 1983. Amikacin in the treatment of pulmonary tuberculosis. Tubercle 64:111-118[CrossRef][Medline]. |
| 2. | Bastian, I., and R. Colebunders. 1999. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 58:633-666[CrossRef][Medline]. |
| 3. | Bastian, I., L. Rigouts, A. Van Deun, and F. Portaels. 2000. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull. W. H. O. 78:238-251[Medline]. |
| 4. | Bergmann, J. S., G. Fish, and G. L. Woods. 2000. Evaluation of the BBL MGIT (mycobacterial growth indicator tube) AST SIRE system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis to 4 primary antituberculous drugs. Arch. Pathol. Lab. Med. 124:82-86[Medline]. |
| 5. | Canetti, G., W. Fox, A. Khomenko, H. T. Mahler, M. K. Menon, D. A. Mitchison, N. Rist, and N. A. Ämelov. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. W. H. O. 41:21-43[Medline]. |
| 6. |
Coninx, R.,
G. E. Pfyffer,
C. Mathieu,
D. Savina,
M. Debacker,
F. Jafarov,
I. Jabrailov,
A. Ismailov,
F. Mirzoev,
R. de Haller, and F. Portaels.
1998.
Drug resistant tuberculosis in prisons in Azerbaijan: case study.
Br. Med. J.
316:1423-1425 |
| 7. | Drobniewski, F., E. Tayler, N. Ignatenko, J. Paul, M. Connolly, P. Nye, T. Lyagoshina, and C. Besse. 1996. Tuberculosis in Siberia. 2. Diagnosis, chemoprophylaxis and treatment. Tuber. Lung Dis. 77:297-301[Medline]. |
| 8. |
Franzblau, S. G.,
R. S. Witzig,
J. C. McLaughlin,
P. Torres,
G. Madico,
A. Hernandez,
M. T. Degnan,
M. B. Cook,
V. K. Quenzer,
R. M. Ferguson, and R. H. Gilman.
1998.
Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.
J. Clin. Microbiol.
36:362-366 |
| 9. |
Goloubeva, V.,
M. Lecocq,
P. Lassowsky,
F. Matthys,
F. Portaels, and I. Bastian.
2001.
Evaluation of Mycobacteria Growth Indicator Tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital.
J. Clin. Microbiol.
39:1501-1505 |
| 10. | Heifets, L. 1988. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob. Agents Chemother. 33:1298-1301. |
| 11. | Heifets, L. 2000. Conventional methods for antimicrobial susceptibility testing of Mycobacterium tuberculosis, p. 133-143. In I. Bastian, and F. Portaels (ed.), Multidrug-resistant tuberculosis. Kluwer Academic Publications, Dordrecht, The Netherlands. |
| 12. |
Iseman, M. D.
1993.
Treatment of multidrug-resistant tuberculosis.
N. Engl. J. Med.
329:784-791 |
| 13. | Kent, P. T., and G. P. Kubica. 1985. Public health mycobacteriology. A guide for the level III laboratory. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga. |
| 14. | Laszlo, A., M. Rahman, M. Raviglione, F. Bustreo, and the W. H. O./IUATLD Network of Supranational Reference Laboratories. 1997. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the W. H. O./IUATLD supranational laboratory network: first round of proficiency testing. Int. J. Tuberc. Lung Dis. 1:231-238[Medline]. |
| 15. |
Pablos-Méndez, A.,
M. C. Raviglione,
A. Laszlo,
N. Binkin,
H. l. Rieder,
F. Bustreo,
D. L. Cohn,
C. S. B. Lambregts-van Weezenbeek,
S. J. Kim,
P. Chaulet, and P. Nunn for the World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Antituberculosis Drug Resistance Surveillance..
1998.
Global surveillance for antituberculosis-drug resistance, 1994-1997.
N. Engl. J. Med.
338:1641-1649 |
| 16. | Palomino, J. C., and F. Portaels. 1999. Simple procedure for drug susceptibility testing of Mycobacterium tuberculosis using a commercial colorimetric assay. Eur. J. Clin. Microbiol. Infect. Dis. 18:380-383[CrossRef][Medline]. |
| 17. | Palomino, J. C., H. Traore, K. Fissette, and F. Portaels. 1999. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 3:344-348[Medline]. |
| 18. |
Pfyffer, G. E.,
D. A. Bonato,
A. Ebrahimzadeh,
W. Gross,
J. Hotaling,
J. Kornblum,
A. Laszlo,
G. Roberts,
M. Salfinger,
F. Wittwer, and S. Siddiqi.
1999.
Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs using the radiometric BACTEC 460 technique and the proportion method with solid media.
J. Clin. Microbiol.
37:3179-3186 |
| 19. |
Rüsch-Gerdes, S.,
C. Domehl,
G. Nardi,
M. R. Gismondo,
H.-M. Welscher, and G. E. Pfyffer.
1999.
Multicenter evaluation of the mycobacterial growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.
J. Clin. Microbiol.
37:45-48 |
| 20. |
Suzuki, Y.,
C. Katsukawa,
A. Tamaru,
C. Abe,
M. Makino,
Y. Mizuguchi, and H. Taniguchi.
1998.
Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene.
J. Clin. Microbiol.
36:1220-1225 |
| 21. | Yajko, D. M., J. J. Madej, M. V. Lancaster, C. A. Sanders, V. L. Cawthon, B. Gee, A. Babst, and W. H. Hadley. 1995. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J. Clin. Microbiol. 33:2324-2327[Abstract]. |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |